The latest study will test setidegrasib versus docetaxel in second-line lung cancer.
ApexOnco Front Page
Recent articles
What could be the four HengRui assets picked up by Bristol?
As the non-muscle invasive space is carved up, Aura tries to seize part of it.
Pre-chemo prostate cancer beckons, but Pluvicto has a long way to go to hit $5bn sales.
At least 15 dual-payload ADCs will be discussed.
In first-line SCLC BNT327 looks better than Tecentriq, but data will need to be replicated outside China.
Novel targets including Ly6E and LRRC15 feature alongside more popular mechanisms.
On key measures Keynote-D77 shows subcutaneous delivery to be the equal of IV.